These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 28032257

  • 1. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
    Fang J, Li W, Peng X, Tan Z, Tan M, Zhang C, Wang W, Xu Z, Zhou G.
    Int Urol Nephrol; 2017 Mar; 49(3):475-482. PubMed ID: 28032257
    [Abstract] [Full Text] [Related]

  • 2. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation.
    Chen YM, Chen HH, Huang WN, Chen YH, Hsieh TY, Yang SS, Lan JL, Chen DY.
    Int J Rheum Dis; 2019 Jun; 22(6):1145-1151. PubMed ID: 31117160
    [Abstract] [Full Text] [Related]

  • 5. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan.
    Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arii K, Kitaori T, Hagiyama H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S.
    Ann Rheum Dis; 2017 Jun; 76(6):1051-1056. PubMed ID: 27934678
    [Abstract] [Full Text] [Related]

  • 6. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zou S.
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [Abstract] [Full Text] [Related]

  • 7. The effects of nucleoside analogue prophylactic treatment on HBV activation in HBcAb+ patients undergoing immunosuppressive therapy.
    Liu HL, Zhao Z, Yang H, Liu FF, Liu Q, Luo Q, Yuan Q, Chen LM, Zeng AZ.
    J Viral Hepat; 2013 Sep; 20(9):645-9. PubMed ID: 23910649
    [Abstract] [Full Text] [Related]

  • 8. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
    Tien YC, Yen HH, Chiu YM.
    Clin Exp Rheumatol; 2017 Sep; 35(5):831-836. PubMed ID: 28375829
    [Abstract] [Full Text] [Related]

  • 9. Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study.
    Tien YC, Yen HH, Li CF, Liu MP, Hsue YT, Hung MH, Chiu YM.
    Arthritis Res Ther; 2018 Nov 01; 20(1):246. PubMed ID: 30382902
    [Abstract] [Full Text] [Related]

  • 10. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.
    Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M.
    BMC Gastroenterol; 2014 Feb 17; 14():31. PubMed ID: 24533834
    [Abstract] [Full Text] [Related]

  • 11. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS.
    Eur J Cancer; 2013 Nov 17; 49(16):3486-96. PubMed ID: 23910494
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
    Borentain P, Colson P, Coso D, Bories E, Charbonnier A, Stoppa AM, Auran T, Loundou A, Motte A, Ressiot E, Norguet E, Chabannon C, Bouabdallah R, Tamalet C, Gérolami R.
    J Viral Hepat; 2010 Nov 17; 17(11):807-15. PubMed ID: 20002298
    [Abstract] [Full Text] [Related]

  • 14. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis.
    Morisco F, Guarino M, La Bella S, Di Costanzo L, Caporaso N, Ayala F, Balato N.
    BMC Gastroenterol; 2014 Dec 19; 14():214. PubMed ID: 25523080
    [Abstract] [Full Text] [Related]

  • 15. Effect of different hepatitis B infection status on the prognosis of active lupus nephritis treated with immunosuppression: a retrospective analysis of 177 patients.
    Fang J, Li W, Tan M, Peng X, Tan Z, Wang W.
    Int J Rheum Dis; 2018 May 19; 21(5):1060-1067. PubMed ID: 29878614
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
    Chen KL, Chen J, Rao HL, Guo Y, Huang HQ, Zhang L, Shao JY, Lin TY, Jiang WQ, Zou DH, Hu LY, Wirian ML, Cai QQ.
    Chin J Cancer; 2015 May 28; 34(5):225-34. PubMed ID: 26058465
    [Abstract] [Full Text] [Related]

  • 18. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: How rational are our prophylaxis decisions according to the literature?
    Yenilmez E, Cetinkaya RA.
    Infez Med; 2019 Sep 01; 27(3):299-307. PubMed ID: 31545774
    [Abstract] [Full Text] [Related]

  • 19. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
    Tang Z, Li X, Wu S, Liu Y, Qiao Y, Xu D, Li J.
    Hepatol Int; 2017 Sep 01; 11(5):429-433. PubMed ID: 28856548
    [Abstract] [Full Text] [Related]

  • 20. Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Zhang A, Wu Y, Tan Y, Shi J, Zhao Y, Hu Y, Yu J, Zheng W, Lai X, Zhang M, Zhu Y, Ye Y, Huang Y, Fu S, Huang H, Luo Y.
    Biol Blood Marrow Transplant; 2020 May 01; 26(5):956-964. PubMed ID: 31962163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.